Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH21 Combined With D-1553 in KRASG12C Mutated Solid Tumors
NCT07318649Phase 2Not yet recruiting
- Sponsor
- Genhouse Bio
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GH21 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Genhouse Bio. Primary endpoint: Objective Response Rate at 2 years. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
GH21
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07318649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318649.